Y-Intercept (HK)’s Inovio Pharmaceuticals INO Stock Holding History

Y-Intercept (HK)’s Portfolio INO Stock Details INO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-42,171	Closed	-$85.8K	–	1787
2025 Q2	$85.8K	Buy	+42,171	New	+$80.8K	﹤0.01%	1543
2024 Q2	–	Sell	-15,245	Closed	-$212K	–	1627
2024 Q1	$212K	Buy	+15,245	New	+$132K	0.02%	1131
2023 Q3	–	Sell	-52,801	Closed	-$283K	–	1300
2023 Q2	$283K	Buy	+52,801	New	+$426K	0.03%	794
2022 Q4	–	Sell	-3,372	Closed	-$69.8K	–	1159
2022 Q3	$69.8K	Buy	+3,372	New	+$86.3K	0.01%	902
2021 Q3	–	Sell	-1,388	Closed	-$154K	–	770
2021 Q2	$154K	Buy	+1,388	New	+$133K	0.04%	548

Other funds holding INO

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BCM

Boxer Capital Management San Diego, California $762M AUM 1,125.36% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Y-Intercept (HK)'s INO Position: Q3 2025 in Review

Y-Intercept (HK) sold out of Inovio Pharmaceuticals (INO) in Q3 2025, closing a stake of 42,171 shares — an estimated $85.8K sold.

Y-Intercept (HK) first reported a position in INO in Q2 2021 and held it in 5 quarters. The position peaked at $283K in Q2 2023. 99 funds tracked by Wall St. Rank hold INO as of Q3 2025.

Y-Intercept (HK) reported no remaining Inovio Pharmaceuticals position as of Q3 2025 after selling out during the quarter.
Y-Intercept (HK) sold 42,171 Inovio Pharmaceuticals shares in Q3 2025, an estimated $85.8K.
Y-Intercept (HK) first reported a position in Inovio Pharmaceuticals in Q2 2021 and held it in 5 quarters.
Y-Intercept (HK)'s Inovio Pharmaceuticals position peaked at $283K in Q2 2023.
99 funds tracked by Wall St. Rank held Inovio Pharmaceuticals as of Q3 2025.

Based on Y-Intercept (HK)'s 13F filing for Q3 2025, filed 31 Oct 2025.